Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 209

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 209
---
 | Licensor(s)       |     | Licensee                       |     | Licensed / IP Rights                                                         |     | Patent Expiration Dates                                                     |
| Acticule / ALS-4               |     | Exclusive Patent License Agreement, dated October 18, 2017          
 First Amendment to Exclusive License Agreement, dated June 7, 2018  
 Second Amendment to Exclusive License Agreement dated July 10, 2019 
 Exclusive Patent License Agreement dated January 11, 2019           |     | Versitech Limited |     | Acticule Life Sciences Limited |     | Exclusive licensee: 2 pending U.S. applications (16/867,540 and 17/006,985), 
 2 pending applications in Canada                                             |     | The licensed IP rights include granted patents in the U.S. and pending      
 patent applications in the U.S., and Canada.                                
 The U.S. patents will expire in 2038; any other patent based on the         
 pending application, if granted, will have a 20-year patent term from 2018. |

Because of the extensive time
required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drug candidates
can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing
any advantage of any such patent. If appropriate, the Company may seek to extend the period during which it has exclusive rights to a
product by pursuing patent term extensions and marketing exclusivity periods that are available from the regulatory authorities of certain
countries (including the United States) and the EPO.

Even though the Company has
certain patent rights, the ability to obtain and maintain protection of biotechnology and pharmaceutical products and processes such as
those we intend to develop and commercialize involves complex legal and factual questions. No consistent policy regarding the breadth
of claims allowed in such patents has emerged to date in the U.S. The scope of patent protection outside the United States is even more
uncertain. Changes in the patent laws or in interpretations of patent laws in the United States and other countries have diminished (and
may further diminish) our ability to protect our inventions and enforce our IP rights and, more generally, could affect the value of IP.

While we have already secured
rights to a number of issued patents directed to our drug candidates, we cannot predict the breadth of claims that may issue from the
pending patent applications and provisional patents that we have licensed or that we